Goldman Sachs
BLTE

Goldman Sachs’s Belite Bio BLTE Stock Holding History

Goldman Sachs’s Portfolio BLTE Stock Details BLTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.6M Buy
166,188
+60,679
+58% +$9.3M ﹤0.01% 2405
2026
Q1 		$16.8M Buy
105,509
+60,910
+137% +$10.2M ﹤0.01% 2600
2025
Q4 		$7.13M Buy
44,599
+40,893
+1,103% +$4.84M ﹤0.01% 3418
2025
Q3 		$274K Buy
+3,706
New +$243K ﹤0.01% 5803
2025
Q1 		– Sell
-6,326
Closed -$399K – 6078
2024
Q4 		$399K Buy
+6,326
New +$417K ﹤0.01% 5361

Other funds holding BLTE

DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $44.4B AUM 57.89% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs's BLTE Position: Q2 2026 in Review

Goldman Sachs increased its Belite Bio (BLTE) stake by 58% in Q2 2026, buying an estimated $9.3M and bringing the position to 166,188 shares worth $25.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2405.

Goldman Sachs first reported a position in BLTE in Q4 2024 and has held it in 5 quarters since. 80 funds tracked by Wall St. Rank hold BLTE as of Q2 2026.

  • Goldman Sachs held 166,188 shares of Belite Bio worth $25.6M as of Q2 2026.
  • Goldman Sachs bought 60,679 Belite Bio shares in Q2 2026, an estimated $9.3M.
  • Belite Bio made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #2405 holding.
  • Goldman Sachs first reported a position in Belite Bio in Q4 2024 and has held it in 5 quarters since.
  • 80 funds tracked by Wall St. Rank held Belite Bio as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.